top of page
Search

Organs-on-Chips Market 2025–2034 | Size, Share & Growth Trends

  • Writer: Pallavi Garudkar
    Pallavi Garudkar
  • 3 days ago
  • 3 min read

According to Fortune Business Insights the global organs-on-chips market size was valued at USD 210.43 million in 2025 and is projected to grow from USD 283.95 million in 2026 to USD 1,993.10 million by 2034, exhibiting a CAGR of 27.58% during the forecast period. North America dominated the Organs On Chips Market with a market share of 43.80% in 2025. The Organs-On-Chips Market comprises microfluidic devices that replicate the biological structure and functions of human organs on a chip-sized platform. These systems simulate human physiology by combining living cells with engineered microenvironments, enabling more accurate evaluation of drug efficacy, toxicity, and disease behavior. Organs-on-chips are increasingly used as alternatives to traditional animal testing models across pharmaceutical research, biotechnology development, and academic studies.

Market Size & Growth Outlook

Why is the organs-on-chips market growing rapidly?

The market is growing rapidly due to increasing adoption of organs-on-chips in drug discovery and preclinical testing applications.

How do investments in life sciences impact market growth?

Rising investments in life sciences research and personalized medicine are accelerating the expansion of the organs-on-chips market.

What is the expected growth outlook for the organs-on-chips market?

The market is expected to register strong double-digit growth over the forecast period, supported by increasing commercialization and growing regulatory acceptance.

Key Market Drivers

Why is there a growing need for organs-on-chips in drug discovery?

There is a growing need for physiologically relevant human models that improve the accuracy of drug efficacy and toxicity testing.

How does pharmaceutical and biotechnology R&D expenditure drive this market?

Rising R&D spending by pharmaceutical and biotechnology companies is increasing demand for advanced in-vitro testing platforms such as organs-on-chips.

What role do ethical and regulatory factors play in market growth?

Increasing ethical concerns and regulatory pressure to reduce animal testing are encouraging the adoption of organs-on-chips technologies.

How do technological advancements support the organs-on-chips market?

Advancements in microfluidics, biomaterials, and cell engineering enhance device functionality and expand application potential.

How is the application scope of organs-on-chips expanding?

The technology is increasingly being used for disease modeling and personalized medicine, broadening its market reach.

Market Segmentation

By Product Type

  • Single-organ chips (lung, liver, heart, kidney, intestine, brain)

  • Multi-organ / body-on-chip systems

By Application

  • Drug discovery and development

  • Toxicity and safety testing

  • Disease modeling

  • Personalized medicine

By End User

  • Pharmaceutical and biotechnology companies

  • Academic and research institutes

  • Contract research organizations (CROs)

  • Cosmetics and chemical industries

Regional Insights

  • North America dominates the market due to strong pharmaceutical infrastructure, high R&D investments, and early adoption of advanced testing technologies.

  • Europe holds a significant share, supported by regulatory encouragement for alternatives to animal testing and robust biomedical research activity.

  • Asia Pacific is emerging as a high-growth region driven by expanding biotech hubs, increasing research funding, and growing pharmaceutical manufacturing.

  • Latin America and Middle East & Africa show steady growth potential supported by increasing research collaborations and healthcare innovation initiatives.

Key Companies Operating in the Market

  • Emulate (U.S.)

  • MIMETAS B.V. (U.S.)

  • InSphero (Switzerland)

  • SynVivo, Inc. (U.S.)

  • CN Bio Innovations Ltd (U.K.)

  • TissUse GmbH (Germany)

  • BICO (Sweden)

  • AlveoliX AG (Switzerland)

Key Industry Development:

  • October 2025: CN Bio Innovations Ltd. launched PhysioMimix Core, the first all-in-one Organ-on-a-Chip (OOC) system, delivering validated performance across single-organ, multi-organ, and high-throughput configurations within a single microphysiological system.

  • September 2025: The Royal Veterinary College (RVC) partnered with Emulate to develop organ-on-a-chip models, pioneering veterinary & preclinical applications and expanding access to this technology for research.

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Address:

Fortune Business Insights Pvt. Ltd.

9th Floor, Icon Tower, Baner –

Mahalunge Road, Baner, Pune-411045,

Maharashtra, India.

Phone

US: +18339092966

UK: +448085020280

APAC: +91 744 740 1245Email: sales@fortunebusinessinsights.com


 
 
 

Comments

bottom of page